Global Business Reports


Lucrezia Falcidia, Jason Spizer

United States Biopharmaceuticals 2020

May 15, 2020

Never before has the pharmaceutical industry faced greater challenges than now, as the whole world is looking to science for a solution to the COVID-19 global pandemic that can allow our societies to function once more. Much of this focus is naturally on the country that has been forcing back the boundaries of medicine like no other. The US is undoubtedly the world leader in bringing innovative therapeutics to market, and novel technologies currently being developed and commercialized are at record levels. An effective response to the COVID-19 pandemic requires unprecedented collaboration across academia, the private sector, and the philanthropic community. These are all areas in which the country excels. America, and in particular its leading clusters on the east coast, has a university system that is the envy of the world, as well as tech transfer, large pharma, fast growing biotech, important corporate partnerships, a well functioning incubator system, and an abundance of talent, skills and know-how regarding discovery, clinical trials and commercialization. These qualities, along with access to liquid and efficient capital markets, power the engine of the US biopharma industry.


Nivagen is engaged in the development, acquisition and sales of generic prescription drugs and OTC products for the North American market.
Aphios’ vision is to develop biotechnology products for improving health and treating chronic diseases in an environmentally sustainable manner.
AzurRx BioPharma is a development stage biopharmaceutical company focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome related conditions.
AiCure is an AI and advanced data analytics company targeting the health industry.


United States Life Sciences 2023

In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.



"With mining companies currently enjoying high prices, exceptional production performance and robust supply chains, we anticipate that the sector will continue showing resilience and growth, remaining financially sound in 2023."